Martin Zweig Detailed Fundamental Analysis

Validea's guru fundamental report ranks Elevance Health (ELV) as the best fit among its 22 models under Martin Zweig's Growth Investor approach, assigning a 69% score that reflects attractive valuation metrics and accelerating recent EPS. The stock passes P/E, current-quarter earnings and insider-transaction tests but fails on sales growth rate, multi-quarter earnings persistence and long-term EPS growth, indicating model-driven moderate interest while flagging concerns about sustainability of growth.

Analysis

Market structure: Elevance (ELV) looks to be a near‑term winner from improving earnings momentum, reasonable P/E and insider buying, while Medicaid‑heavy peers (e.g., CNC) and providers facing rate pressure are relative losers. If ELV’s EPS acceleration is driven by pricing power in Medicare Advantage and commercial book, it can steal share/GM% versus weaker managed‑care operators; higher interest rates should incrementally boost insurer investment income while compressing equity multiples.

Risk assessment: Key tail risks are regulatory caps on MA rate increases, reserve shortfalls from adverse claims, and a rollback of buybacks (which could reverse EPS gains); these could materialize over weeks to quarters. Immediate market reaction will hinge on next quarterly print (days–weeks); medium term (1–4 quarters) depends on medical‑trend normalization; long term (2+ years) the failure to restore sales growth implies limited multiple expansion.

Trade implications: Tactical long exposure to ELV ahead of the next 30–60 day earnings/CMS rate windows is warranted but size should be capped given long‑term growth failings—use defined‑risk structures (call spreads/collars). Relative‑value: go long ELV vs short CNC (1:1) to express better margin/MA positioning; hedge macro with 3‑6 month puts if implied vol spikes or if insider selling resumes.

Contrarian angles: The consensus may overweight sales weakness and underweight EPS quality driven by buybacks/mix—if medical cost trends decelerate 200–300 bps over 6–12 months ELV could rerate 10–20%. Conversely, regulatory action or a >$50m insider sell program would be an asymmetric negative; set explicit stop/triggers to avoid regime change losses.

Key Decisions for Investors

• Consider establishing a 2–3% long position in ELV within the next 2–6 weeks, conditional on forward P/E ≤ 16 or an upcoming quarterly EPS beat; target 12‑month upside 15–25% and place a hard stop at a 10–12% loss.
• Implement a pair trade: long ELV / short CNC (Centene) 1:1 sized 1–2% net exposure to capture relative margin/MA resilience over 3–9 months; unwind if ELV outperforms by >8% or if ELV misses two consecutive quarters of guidance.
• Use options for defined risk: buy a 3‑month ELV call spread (buy 5% OTM, sell 15% OTM) sized to risk ~0.5% portfolio ahead of earnings; if short‑term IV >30%, switch to a July 2026 call spread to play re‑rating with lower time‑decay risk.
• Monitor specific catalysts for 30–90 days: CMS Medicare Advantage rate notice, next quarterly EPS/guidance, and Form 4 insider filings. Reduce exposure to zero if insiders sell >$50m in 30 days or guidance is cut by >3%.